ABBV Nov 2019 74.000 call

OPR - OPR Delayed Price. Currency in USD
10.36
0.00 (0.00%)
As of 11:07AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close10.36
Open10.36
Bid12.25
Ask12.75
Strike74.00
Expire Date2019-11-22
Day's Range10.36 - 10.36
Contract RangeN/A
Volume1
Open Interest58
  • PR Newswire

    AbbVie to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at 2019 ASH Annual Meeting

    - AbbVie will present more than 40 abstracts featuring data from approved and investigational medicines - New minimal residual disease (MRD) data from CAPTIVATE clinical trial evaluating ibrutinib (IMBRUVICA®) ...

  • GlobeNewswire

    Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, and AbbVie Inc. (ABBV), a global biopharmaceutical company, today announced an exclusive worldwide option and license transaction for HPN217, Harpoon’s B cell maturation antigen (BCMA)-targeting Tri-specific T cell Activating Construct (TriTAC®), and an expansion of their existing discovery collaboration for up to six additional targets.

  • Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - November 20, 2019
    Zacks

    Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - November 20, 2019

    The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

  • Myovant Up on Successful Completion of Prostate Cancer Study
    Zacks

    Myovant Up on Successful Completion of Prostate Cancer Study

    Myovant's (MYOV) phase III study evaluating lead pipeline candidate, relugolix, in patients with advanced prostate cancer meets primary endpoint.

  • Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology
    CNW Group

    Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology

    Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology

  • 5 Corporate Giants That Popped After Latest Earnings Release
    Zacks

    5 Corporate Giants That Popped After Latest Earnings Release

    A few corporate behemoths that reported their last earnings results less than five weeks ago, popped after releasing earnings results.

  • Drug Legislation Likely to Dry Up Biotech Funding
    GuruFocus.com

    Drug Legislation Likely to Dry Up Biotech Funding

    Industry executives claim the proposed law will inhibit the development of life-saving medications Continue reading...

  • Pfizer Gets FDA Approval for Biosimilar of AbbVie's Humira
    Zacks

    Pfizer Gets FDA Approval for Biosimilar of AbbVie's Humira

    The approval of Humira biosimilar is the fourth U.S. approval of a biosimilar product for Pfizer (PFE) in 2019.

  • MoneyShow

    AbbVie- On the Cutting Edge

    AbbVie Inc. (ABBV) is a cutting-edge U.S. based biopharmaceutical company specializing in drugs and treatments that incorporate biotechnology as a solution to human diseases, explains growth and income expert Tom Hutchinson, editor of Cabot Dividend Investor.

  • PR Newswire

    AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes

    NORTH CHICAGO, Ill. , Nov. 18, 2019 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the extension of the expiration date of the offers to exchange (each, an "Exchange ...

  • AbbVie's Humira on Pace to Become Biggest Seller by 2024
    GuruFocus.com

    AbbVie's Humira on Pace to Become Biggest Seller by 2024

    Immunology drug scheduled to supplant the widely used heart medication Lipitor, tallying cumulative sales of $240 billion Continue reading...

  • Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates
    Zacks

    Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates

    Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.

  • 4 Big Drugmakers to Bet on After a Great Earnings Season
    Zacks

    4 Big Drugmakers to Bet on After a Great Earnings Season

    Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.

  • Financial Times

    Credit market fears of downgrades have not materialised

    Like a lapsing gym membership, companies’ commitments to go on a debt diet this year have been showing signs of waning. from bond investors to help fund its $83bn acquisition of Allergan, pushing its total debt outstanding close to $100bn and making it one of the most indebted companies in the world. of drugstore Walgreens Boots Alliance by private equity firm KKR — a deal that could involve another borrowing splurge.

  • Seth Klarman Exits Allergan, Buys 3 New Positions in 3rd Quarter
    GuruFocus.com

    Seth Klarman Exits Allergan, Buys 3 New Positions in 3rd Quarter

    Baupost manager reports quarterly portfolio Continue reading...

  • MarketWatch

    Exicures shares up on Allergan partnership

    Shares of Exicure are up 26% in premarket trading on the news that the biotechnology company entered into an agreement with Allergan to develop treatments for hair loss disorders. Exicure will receive an upfront payment of $25 million. In addition, it can receive milestone payments up to $97.5 million per R&D program and up to $265 million per commercial program. Allergan's portfolio has long been known for top-selling beauty brands like the medical fillers Botox and Juvéderm. Its $63 billion acquisition by AbbVie is expected to close early next year. Exicure stock is down 30.51% year-to-date, while the S&P 500 has risen 23%.

  • Barrons.com

    Beware of Runs on Bond Funds

    In a less favorable market, however, bond fund investors could get hurt—not so much by worsening fundamentals, but the funds’ difficulty to meet redemptions in an illiquid market. As much as 50% of the assets in high-yield bond funds and 15% of assets of all fixed-income funds could be vulnerable to a liquidity shortfall in the event of heavy investor redemptions. “There are more risks to open-end bond funds than people are willing to acknowledge,” says Mark Grant, chief global strategist B. Riley FBR.

  • Barrons.com

    AbbVie Sold $30 Billion in Bonds, and Two More Numbers to Know

    You may have heard that number cited recently as the value of an asteroid called 16 Psyche . If humans ever manage to mine the asteroid, a flood of space-gold would completely crater the terrestrial market. All that extra supply would cause today’s gold price to plummet.

  • Should Investors Add Johnson & Johnson Stock to Their Shopping Lists?
    InvestorPlace

    Should Investors Add Johnson & Johnson Stock to Their Shopping Lists?

    On Oct. 15, Johnson & Johnson (NYSE:JNJ), the healthcare giant, reported Q3 earnings and revenue that beat analysts' average expectations. Yet, over the past 12 months, JNJ stock is down about 9%.Source: Alexander Tolstykh / Shutterstock.com Now many investors are wondering whether the company may end the year on a high note. In the next few weeks, I expect Johnson & Johnson shares to trade mostly between a range of $125 and $135. Long-term investors may view any upcoming weakness in the JNJ stock price as an opportunity to buy the shares. Analyzing JNJ's Recent EarningsWith a market cap of $347 billion, Johnson & Johnson, the healthcare giant, is currently number 37 on the Fortune 500 list. JNJ 's third-quarter revenue rose 1.9% year-over-year to $20.7 billion. Its earnings per share, excluding certain items, came in at $2.12, versus analysts' average estimate of $2.01.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Tech Stocks to Buy for the Rest of 2019 The company has a broad-based business model with a global reach. It operates in three segments that provide it with diversified sources of revenue, earnings and cash flow: * Pharmaceutical, which contributes more than 50% of JNJ's pretax profits * Consumer * Medical DevicesJNJ's pharmaceutical division markets treatments for immunology, cardiovascular and metabolic diseases, pulmonary hypertension, infectious diseases and cancer.Several of its well-known consumer brands include Aveeno, Band-Aid, Johnson's Baby, Listerine, Neutrogena, Rogaine, Tylenol and Zyrtec.Finally,its medical devices business develops and markets products and solutions for surgery, orthopedics, and vision.Although about 60% of Johnson &Johnson's revenue is U.S.-based, its overseas operations in general and its emerging market businesses in particular are proving to be important growth catalysts for JNJ. The Legal Woes of Johnson & JohnsonPharmaceutical industry firms often face legal challenges. At present, Johnson & Johnson is facing literally thousands of lawsuits.For example, in the summer, the Federal Trade Commission issued civil subpoenas to the company in an effort to determine whether JNJ had violated antitrust laws with Remicade, its rheumatoid arthritis drug.In August, Johnson and Johnson made the news when an Oklahoma judge found it guilty of helping to fuel the state's opioid crisis by aggressively marketing painkillers. JNJ is also facing various lawsuits regarding its talc-based baby powder.Recent research by Theresa Gabaldon of George Washington University Law School discusses in detail the "ballooning of pharmaceutical advertising with correlative increases in the prescriptions written for various mental and other ailments" within the industry.Professor Gabaldon further states that "Purdue Pharma led off in the 1990s by heavily advertising OxyContin as non-addictive--a claim that clearly was untrue." AbbVie (NYSE:ABBV), Johnson & Johnson, and Pfizer (NYSE:PFE) "also conducted aggressive advertising campaigns for their proprietary opioids. These campaigns, which were directed at physicians, resulted in $11 billion from opioid sales alone in 2010."In the long-run, lawsuits and fines do not necessarily dent the fundamental metrics of pharma companies much. However, in the short-term, investors understandably get spooked by the uncertainty created by lawsuits. Other Long-Term Factors to ConsiderOne of the challenges faced by JNJ and other drug companies is falling sales as the patents of blockbuster drugs expire, enabling much cheaper, competing generic drugs to be sold.Therefore, the pressure to innovate and diversify is part of the reality of managing a global pharma leader like Johnson & Johnson. And in JNJ's case, diversification has been the company's competitive advantage. As one segment faces headwinds, the others usually help propel the company forward.The forward price-earnings ratio of JNJ stock stands at 14.5 and is lower than many of its peers. Many investors would cbe comfortable paying more than that for a strong business like Johnson & Johnson.Meanwhile, Johnson & Johnson stock also has a dividend yield of 2.9%. The conglomerate has raised its dividend each year for over half a century. And dividends tend to create a "price floor" for coveted stocks such as JNJ. What Technical Charts IndicateNo investor has a crystal ball that can predict the markets' next move. However, analyzing the recent price action of JNJ stock may give us an indication of what to expect in the weeks ahead.In 2019 JNJ stock has fallen 1.6%. Its 52-week range has been $121.00 (Dec. 24, 2018) - $148.99 (Dec. 4, 2018).JNJ's short-term charts are painting a mixed picture and suggest that JNJ stock is likely to trade within a range. While long-term investors would like to see JNJ stock stay over $135, short-term traders are likely to keep the shares between $125 and $135.I do not expect Johnson & Johnson stock to reach any new highs until we have more clarity on the full ramification of several of its legal challenges.In recent weeks, the stock has found support around the $125 level. Therefore, I'd consider buying the shares if they fall toward or even below first $125 and then $120. The Bottom Line on JNJ StockThe company's diversification enables JNJ stock to withstand economic cycles more effectively. No matter what the economy does, consumers will buy the products of many of its strong brands, and Johnson & Johnson will likely have industry-leading market share in many areas.I remain bullish on the long-term outlook of Johnson and Johnson stock. However, in the short-term, JNJ might exhibit weakness.Therefore, investors may consider staying on the sidelines on JNJ if they do not currently have a position in the shares.Alternatively, investors who already own the shares may consider hedging their positions. As for hedging strategies, covered calls with a Jan. 17 expiry could be appropriate.Finally, any short-term decline in these shares may create better entry points for long-term investors who do not yet own JNJ stock.As of this writing, Tezcan Gecgil hold PFE covered calls (Nov. 15 expiry). More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks to Buy for the Rest of 2019 * 7 Biotech Stocks to Buy With Plenty of Power in the Pipeline * 5 Stocks to Buy That Are Set for Monster Growth in 2020 The post Should Investors Add Johnson & Johnson Stock to Their Shopping Lists? appeared first on InvestorPlace.

  • AbbVie Takes on Debt to Buy Allergan
    GuruFocus.com

    AbbVie Takes on Debt to Buy Allergan

    The $30 billion corporate loan is intended to finance the acquisition of Allergan Continue reading...

  • Barrons.com

    AbbVie’s $30 Billion Bond Sale Was Wall Street’s Biggest This Year

    Investors were willing to pay up on Tuesday to buy the fourth-biggest corporate bond sale on record. To finance the acquisition, AbbVie sold $30 billion of bonds, in what was also the biggest corporate bond sale this year.

  • Barrons.com

    Abbott Labs Chooses an Insider to Be Its New CEO

    Miles White, who has led the business since 1999, will be succeeded by Robert Ford, president and chief operating officer of the pharmaceutical and medical-devices company.

  • TheStreet.com

    Cash Stashes Dwindle as Markets Crest and Powell Speaks: Market Recon

    Plus, we preview Wednesday's Trump-Erdogan meeting and check out AbbVie's huge debt offering as well as the new Abode-Microsoft connection.

  • PR Newswire

    AbbVie Prices $30 Billion of Senior Unsecured Notes

    NORTH CHICAGO, Ill., Nov. 12, 2019 /PRNewswire/ -- AbbVie Inc. (ABBV) ("AbbVie") announced today that it has priced its previously announced private offering (the "Offering") of senior unsecured notes in a combined aggregate principal amount of $30 billion (collectively, the "Notes"). AbbVie expects that the closing of the Offering will occur on November 21, 2019, subject to the satisfaction of customary closing conditions.